ES2308813T3 - Mutacion en el gen conexina 26 responsable de la sordera prelingual no-sindromica y metodo de deteccion. - Google Patents
Mutacion en el gen conexina 26 responsable de la sordera prelingual no-sindromica y metodo de deteccion. Download PDFInfo
- Publication number
- ES2308813T3 ES2308813T3 ES98945246T ES98945246T ES2308813T3 ES 2308813 T3 ES2308813 T3 ES 2308813T3 ES 98945246 T ES98945246 T ES 98945246T ES 98945246 T ES98945246 T ES 98945246T ES 2308813 T3 ES2308813 T3 ES 2308813T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- dna
- seq
- probe
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 60
- 206010011878 Deafness Diseases 0.000 title claims description 54
- 238000000034 method Methods 0.000 title claims description 35
- 238000001514 detection method Methods 0.000 title claims description 31
- 239000002773 nucleotide Substances 0.000 claims abstract description 18
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 18
- 230000007547 defect Effects 0.000 claims abstract description 15
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 15
- 239000002157 polynucleotide Substances 0.000 claims abstract description 15
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 15
- 230000001953 sensory effect Effects 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 61
- 108020004414 DNA Proteins 0.000 claims description 49
- 208000016354 hearing loss disease Diseases 0.000 claims description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims description 20
- 231100000895 deafness Toxicity 0.000 claims description 19
- 239000013615 primer Substances 0.000 claims description 19
- 238000009396 hybridization Methods 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 15
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 108010069156 Connexin 26 Proteins 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 7
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 7
- 229940029575 guanosine Drugs 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000003155 DNA primer Substances 0.000 claims description 3
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 claims description 3
- 108091081024 Start codon Proteins 0.000 claims description 3
- 238000003936 denaturing gel electrophoresis Methods 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 239000011544 gradient gel Substances 0.000 claims description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102000055974 Connexin 26 Human genes 0.000 claims 2
- 101150044182 8 gene Proteins 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 abstract description 4
- 230000037430 deletion Effects 0.000 abstract description 4
- 229920001184 polypeptide Polymers 0.000 abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 201000006790 nonsyndromic deafness Diseases 0.000 abstract description 2
- 102100037156 Gap junction beta-2 protein Human genes 0.000 description 45
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 description 26
- 208000031514 autosomal recessive nonsyndromic hearing loss 1A Diseases 0.000 description 26
- 101710198067 Gap junction beta-2 protein Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 206010011891 Deafness neurosensory Diseases 0.000 description 8
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 8
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108091027305 Heteroduplex Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000011755 Hearing abnormality Diseases 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150112497 26 gene Proteins 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101100403145 Danio rerio mul1a gene Proteins 0.000 description 1
- 206010011882 Deafness congenital Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010027757 Mixed deafness Diseases 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000036204 autosomal dominant nonsyndromic hearing loss Diseases 0.000 description 1
- 208000036201 autosomal recessive hearing loss Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5586397P | 1997-08-15 | 1997-08-15 | |
| US55863P | 1997-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2308813T3 true ES2308813T3 (es) | 2008-12-01 |
Family
ID=22000653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98945246T Expired - Lifetime ES2308813T3 (es) | 1997-08-15 | 1998-08-14 | Mutacion en el gen conexina 26 responsable de la sordera prelingual no-sindromica y metodo de deteccion. |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US5998147A (enExample) |
| EP (1) | EP1003865B1 (enExample) |
| JP (1) | JP4418587B2 (enExample) |
| AT (1) | ATE399860T1 (enExample) |
| CA (3) | CA2852463C (enExample) |
| CY (1) | CY1108771T1 (enExample) |
| DE (1) | DE69839671D1 (enExample) |
| DK (1) | DK1003865T3 (enExample) |
| ES (1) | ES2308813T3 (enExample) |
| PT (1) | PT1003865E (enExample) |
| WO (1) | WO1999009210A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE399860T1 (de) * | 1997-08-15 | 2008-07-15 | Pasteur Institut | Mutation innerhalb des connexin 26 gens und bezug zu prelingualer syndromloser taubheit sowie detektionsverfahren |
| US6013449A (en) * | 1997-11-26 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Probe-based analysis of heterozygous mutations using two-color labelling |
| WO2002061410A1 (en) * | 2000-09-01 | 2002-08-08 | Spectrumedix Corporation | System and method for temperature gradient capillary electrophoresis |
| WO2002031199A1 (en) * | 2000-10-11 | 2002-04-18 | Spectrumedix Corporation | System and method for determining the presence of methylated cytosines in polynucleotides |
| JP2005504534A (ja) | 2001-09-19 | 2005-02-17 | アメリカ合衆国政府 | トランスダクチン−１及びトランスダクチン−２並びに遺伝性聴覚障害への適用 |
| WO2003033743A1 (en) * | 2001-10-18 | 2003-04-24 | Spectrumedix Corporation | System and method for temperature gradient capillary electrophoresis |
| NL1019226C2 (nl) * | 2001-10-25 | 2003-04-28 | Multigen Holding S A | Werkwijze voor het detecteren van een mutatie die verband houdt met plaveiselcelcarcinoom. |
| EP1308458A1 (en) * | 2001-10-30 | 2003-05-07 | GenOdyssee | New polynucleotides and polypeptides of the CX26 gene |
| US6872530B2 (en) * | 2002-04-24 | 2005-03-29 | Spectrumedix, Llc | Method for determining the presence of DNA variants using peptide nucleic acid probes |
| AU2003253922A1 (en) * | 2002-07-15 | 2004-02-02 | Spectrumedix Llc | System and method for determining known dna variants with temperature gradient electrophoresis |
| WO2004007690A2 (en) * | 2002-07-16 | 2004-01-22 | Spectrumedix Llc | Method and system for comparative genomics for organisms using temperature gradient electrophoresis |
| AU2002952702A0 (en) * | 2002-11-18 | 2002-11-28 | Murdoch Childrens Research Institute | A diagnostic assay |
| US7700750B2 (en) * | 2003-01-09 | 2010-04-20 | Third Wave Technologies, Inc. | Connexin allele detection assays |
| US20040166495A1 (en) * | 2003-02-24 | 2004-08-26 | Greinwald John H. | Microarray-based diagnosis of pediatric hearing impairment-construction of a deafness gene chip |
| US7303879B2 (en) * | 2003-07-31 | 2007-12-04 | Applera Corporation | Determination of SNP allelic frequencies using temperature gradient electrophoresis |
| US7166433B2 (en) | 2004-03-03 | 2007-01-23 | The United States Of America As Represented By The Department Of Health And Human Services | Transductin-1 and transductin-2 and applications to hereditary deafness |
| US7276804B2 (en) * | 2005-06-22 | 2007-10-02 | C.E. Niehoff & Co. | Voltage regulator with improved protection and warning system |
| US20070134691A1 (en) * | 2005-11-21 | 2007-06-14 | Iris Schrijver | Methods and compositions for determining whether a subject carries a gene mutation associated with hereditary hearing loss |
| CA3141309A1 (en) * | 2019-05-22 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Synaptojanin 2 (synj2) variants and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228805A (en) | 1978-11-08 | 1980-10-21 | Rca Corporation | Method of measuring blood perfusion |
| US4709703A (en) | 1985-11-12 | 1987-12-01 | Mayo Foundation | Imaging system and method using radiopaque microspheres for evaluation of organ tissue perfusion |
| US5480382A (en) | 1989-01-09 | 1996-01-02 | Pilot Cardiovascular Systems, Inc. | Steerable medical device |
| US5552541A (en) * | 1990-06-20 | 1996-09-03 | Beckman Instruments, Inc. | Haptenic probes for detecting capture polynucleotides |
| US5190050A (en) | 1991-11-08 | 1993-03-02 | Electro-Catheter Corporation | Tip deflectable steerable catheter |
| US5312415A (en) | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
| US6165139A (en) | 1993-03-01 | 2000-12-26 | Fonar Corporation | Remotely steerable guide wire with external control wires |
| US5769796A (en) | 1993-05-11 | 1998-06-23 | Target Therapeutics, Inc. | Super-elastic composite guidewire |
| US5358479A (en) | 1993-12-06 | 1994-10-25 | Electro-Catheter Corporation | Multiform twistable tip deflectable catheter |
| US5661122A (en) | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
| US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
| EP0725136A1 (en) * | 1995-02-03 | 1996-08-07 | Institut Pasteur | Nucleotide and peptide sequences of the USHER-lB gene diagnostic and therapeutic applications |
| US5855577A (en) | 1996-09-17 | 1999-01-05 | Eclipse Surgical Technologies, Inc. | Bow shaped catheter |
| US6106473A (en) | 1996-11-06 | 2000-08-22 | Sts Biopolymers, Inc. | Echogenic coatings |
| US5967991A (en) | 1996-12-03 | 1999-10-19 | Echocath, Inc. | Drive apparatus for an interventional medical device used in an ultrasonic imaging system |
| US5876373A (en) | 1997-04-04 | 1999-03-02 | Eclipse Surgical Technologies, Inc. | Steerable catheter |
| ATE399860T1 (de) | 1997-08-15 | 2008-07-15 | Pasteur Institut | Mutation innerhalb des connexin 26 gens und bezug zu prelingualer syndromloser taubheit sowie detektionsverfahren |
| US5984929A (en) | 1997-08-29 | 1999-11-16 | Target Therapeutics, Inc. | Fast detaching electronically isolated implant |
| US6179809B1 (en) | 1997-09-24 | 2001-01-30 | Eclipse Surgical Technologies, Inc. | Drug delivery catheter with tip alignment |
| JP4065663B2 (ja) | 1997-10-02 | 2008-03-26 | ボストン サイエンティフィック リミテッド | 繊維を体内へと送達するためのデバイス |
| US6053870A (en) | 1997-11-08 | 2000-04-25 | Angiodynamics, Inc. | Ultrasonic visible surgical needle |
| US6248112B1 (en) | 1998-09-30 | 2001-06-19 | C. R. Bard, Inc. | Implant delivery system |
| US6146339A (en) | 1999-05-24 | 2000-11-14 | Advanced Cardiovascular Systems | Guide wire with operator controllable tip stiffness |
| US6277082B1 (en) | 1999-07-22 | 2001-08-21 | C. R. Bard, Inc. | Ischemia detection system |
-
1998
- 1998-08-14 AT AT98945246T patent/ATE399860T1/de active
- 1998-08-14 US US09/134,566 patent/US5998147A/en not_active Expired - Lifetime
- 1998-08-14 DE DE69839671T patent/DE69839671D1/de not_active Expired - Lifetime
- 1998-08-14 WO PCT/EP1998/005175 patent/WO1999009210A2/en not_active Ceased
- 1998-08-14 ES ES98945246T patent/ES2308813T3/es not_active Expired - Lifetime
- 1998-08-14 EP EP98945246A patent/EP1003865B1/en not_active Expired - Lifetime
- 1998-08-14 PT PT98945246T patent/PT1003865E/pt unknown
- 1998-08-14 JP JP2000509871A patent/JP4418587B2/ja not_active Expired - Lifetime
- 1998-08-14 DK DK98945246T patent/DK1003865T3/da active
- 1998-08-14 CA CA2852463A patent/CA2852463C/en not_active Expired - Lifetime
- 1998-08-14 CA CA2720384A patent/CA2720384C/en not_active Expired - Lifetime
- 1998-08-14 CA CA2301301A patent/CA2301301C/en not_active Expired - Lifetime
- 1998-08-14 US US09/485,415 patent/US6485908B1/en not_active Expired - Lifetime
-
2002
- 2002-10-23 US US10/278,089 patent/US7258975B2/en not_active Expired - Fee Related
-
2007
- 2007-07-12 US US11/826,141 patent/US8143000B2/en not_active Expired - Fee Related
-
2008
- 2008-09-24 CY CY20081101032T patent/CY1108771T1/el unknown
-
2012
- 2012-03-26 US US13/430,062 patent/US8455195B2/en not_active Expired - Fee Related
-
2013
- 2013-05-22 US US13/899,963 patent/US9169517B2/en not_active Expired - Fee Related
-
2015
- 2015-09-18 US US14/858,666 patent/US9868989B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120322059A1 (en) | 2012-12-20 |
| CA2301301C (en) | 2010-12-07 |
| US9868989B2 (en) | 2018-01-16 |
| JP4418587B2 (ja) | 2010-02-17 |
| US9169517B2 (en) | 2015-10-27 |
| EP1003865B1 (en) | 2008-07-02 |
| US8143000B2 (en) | 2012-03-27 |
| US20160076101A1 (en) | 2016-03-17 |
| US6485908B1 (en) | 2002-11-26 |
| WO1999009210A2 (en) | 1999-02-25 |
| CA2720384C (en) | 2014-08-12 |
| US20090104600A1 (en) | 2009-04-23 |
| PT1003865E (pt) | 2008-10-14 |
| US20030170676A1 (en) | 2003-09-11 |
| ATE399860T1 (de) | 2008-07-15 |
| CA2301301A1 (en) | 1999-02-25 |
| US7258975B2 (en) | 2007-08-21 |
| CY1108771T1 (el) | 2014-04-09 |
| WO1999009210A3 (en) | 1999-04-15 |
| DE69839671D1 (de) | 2008-08-14 |
| DK1003865T3 (da) | 2008-11-10 |
| JP2001514904A (ja) | 2001-09-18 |
| CA2720384A1 (en) | 1999-02-25 |
| US5998147A (en) | 1999-12-07 |
| CA2852463C (en) | 2017-08-29 |
| US8455195B2 (en) | 2013-06-04 |
| CA2852463A1 (en) | 1999-02-25 |
| EP1003865A2 (en) | 2000-05-31 |
| US20140113285A1 (en) | 2014-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2308813T3 (es) | Mutacion en el gen conexina 26 responsable de la sordera prelingual no-sindromica y metodo de deteccion. | |
| ES2352417T3 (es) | Método para la detección de una alteración en un ácido nucléico. | |
| Das et al. | Novel missense mutations and a 288‐bp exonic insertion in PAX9 in families with autosomal dominant hypodontia | |
| JP6622731B2 (ja) | 歯周病の重症度および進行を決定するための改良された方法およびキット | |
| Germain et al. | Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the α-galactosidase A gene and detection of carriers in Fabry disease | |
| CN1126496A (zh) | 耳毒性耳聋易感性突变的检测方法 | |
| Damgaard et al. | No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes | |
| Naja et al. | Accurate and rapid prenatal diagnosis of the most frequent East Mediterranean β‐thalassemia mutations | |
| US6218524B1 (en) | Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof | |
| US10770183B2 (en) | Methods of assessing a risk of developing necrotizing meningoencephalitis | |
| Wei et al. | Analysis of four common salt-wasting mutations in CYP21 (steroid 21-hydroxylase) by cleavase fragment length polymorphism analysis and characterization of a frequent polymorphism in intron 6 | |
| JP4889258B2 (ja) | ウシ白血病発症に対する抵抗性の判定方法 | |
| CN116004799B (zh) | Crtap致病突变体及在制备脆骨症ⅶ型诊断试剂盒中的应用 | |
| ES2333518T3 (es) | Metodo y sondas para el diagnostico genetico de la hemocromatosis. | |
| JP4121764B2 (ja) | 血栓形成傾向素因の検査方法 | |
| Appleby | Telomere length as a putative biomarker of health and disease | |
| CN115927585A (zh) | WAS致病突变基因及在制备Wiskott-Aldrich综合征诊断试剂盒中的应用 | |
| Bonaglia et al. | Concurrent transposition of distal 6p and 20q to the 22q telomere: A recurrent benign chromosomal variant | |
| US20050118579A1 (en) | Chemical compounds | |
| Thomas | Methods for investigating the molecular bases of complement terminal component deficiency | |
| JPWO2006098401A1 (ja) | 関節リウマチ罹患リスクの測定方法 | |
| PL226331B1 (pl) | Sposób wykrywania genetycznie uwarunkowanej wysokiej predyspozycji do raka piersi oraz zastosowanie mutacji skracających białko CHEK2 |